ARTIFICIAL INTELLIGENCE IN MEDICAL CHEMISTRY: NEW SCIENTIFIC OPPORTUNITIES

Tojiboyeva Iroda Muhammadyunusovna
Senior Lecturer at the Department of Medical and Biological Chemistry, Tashkent State Medical University
O‘rolboyeva Ozodaxon Jamoliddin qizi
Students of Tashkent State Medical University
Isoqov Qodirbek Ma’rufjon o‘g‘li
Students of Tashkent State Medical University

Abstract. Artificial intelligence has become an essential technological instrument in medical chemistry due to its ability to analyze complex chemical and biological data with high accuracy. Traditional drug discovery methods are characterized by long development times, high financial costs, and high failure rates during clinical trials. According to published pharmaceutical industry data, more than 90% of drug candidates fail before reaching the market, primarily due to toxicity or insufficient therapeutic efficacy. This situation has accelerated the integration of artificial intelligence into medical chemistry. AI-based algorithms are currently used to predict molecular properties, optimize chemical synthesis, identify drug targets, evaluate toxicity, and support personalized medicine. This article examines the scientifically proven role of artificial intelligence in medical chemistry, focusing on concrete data, measurable outcomes, and real-world applications. The use of artificial intelligence has significantly reduced drug development time, improved prediction accuracy, and minimized experimental risks, making it a fundamental component of modern pharmaceutical research.

Keywords: artificial intelligence, medicinal chemistry, drug discovery, molecular modeling, machine learning, predictive analytics, personalized medicine, deep learning, pharmacokinetics, high-throughput screening.

Annotatsiya. Sun’iy intellekt murakkab kimyoviy va biologik ma’lumotlarni yuqori aniqlik bilan tahlil qilish qobiliyati tufayli tibbiy kimyoda muhim texnologik vositaga aylandi. An’anaviy dori vositalarini yaratish usullari uzoq davom etadigan ishlab chiqish jarayonlari, yuqori moliyaviy xarajatlar va klinik sinovlar bosqichida muvaffaqiyatsizlikning yuqori darajasi bilan tavsiflanadi. Farmatsevtika sanoatida e’lon qilingan ma’lumotlarga ko‘ra, dori nomzodlarining 90 foizdan ortig‘i bozorda paydo bo‘lishidan oldin, asosan toksiklik yoki yetarli terapevtik samaradorlikka ega bo‘lmagani sababli muvaffaqiyatsizlikka uchraydi. Ushbu holat tibbiy kimyoga sun’iy intellektni jadal joriy etishga turtki bo‘ldi. Hozirgi vaqtda sun’iy intellektga asoslangan algoritmlar molekulyar xususiyatlarni bashorat qilish, kimyoviy sintezni optimallashtirish, dori nishonlarini aniqlash,

ISSN 3030-3907

toksiklikni baholash va shaxsiylashtirilgan tibbiyotni qo‘llab-quvvatlashda qo‘llanilmoqda. Ushbu maqolada sun’iy intellektning tibbiy kimyodagi ilmiy jihatdan isbotlangan o‘rni aniq ma’lumotlar, o‘lchanadigan natijalar va real amaliy qo‘llanmalar asosida ko‘rib chiqiladi. Sun’iy intellektdan foydalanish dori ishlab chiqish vaqtini sezilarli darajada qisqartirdi, bashorat qilish aniqligini oshirdi va tajriba xavflarini kamaytirdi, bu esa uni zamonaviy farmatsevtik tadqiqotlarning ajralmas tarkibiy qismiga aylantirdi.

Kalit so‘zlar: sun’iy intellekt, tibbiy kimyo, dori yaratish, molekulyar modellashtirish, mashinaviy o‘rganish, bashoratli tahlil, shaxsiylashtirilgan tibbiyot, chuqur o‘rganish, farmakokinetika, yuqori unumli skrining.

Аннотация. Искусственный интеллект стал важнейшим технологическим инструментом в медицинской химии благодаря своей способности с высокой точностью анализировать сложные химические и биологические данные. Традиционные методы разработки лекарственных средств характеризуются длительными сроками создания, высокими финансовыми затратами и высокой долей неудач на этапе клинических испытаний. Согласно опубликованным данным фармацевтической отрасли, более 90% кандидатов в лекарственные препараты не доходят до выхода на рынок, главным образом из-за токсичности или недостаточной терапевтической эффективности. Данная ситуация ускорила интеграцию искусственного интеллекта в медицинскую химию. В настоящее время алгоритмы на основе искусственного интеллекта используются для прогнозирования молекулярных свойств, оптимизации химического синтеза, идентификации лекарственных мишеней, оценки токсичности и поддержки персонализированной медицины. В данной статье рассматривается научно доказанная роль искусственного интеллекта в медицинской химии с акцентом на конкретные данные, измеримые результаты и реальные практические применения. Использование искусственного интеллекта значительно сократило время разработки лекарственных средств, повысило точность прогнозирования и минимизировало экспериментальные риски, что делает его фундаментальным компонентом современных фармацевтических исследований.

Ключевые слова: искусственный интеллект, медицинская химия, разработка лекарственных средств, молекулярное моделирование, машинное обучение, предиктивная аналитика, персонализированная медицина, глубокое обучение, фармакокинетика, высокопроизводительный скрининг.

INTRODUCTION

ISSN 3030-3907

Medical chemistry is a key scientific discipline that focuses on the discovery, synthesis, and optimization of chemical compounds used for the prevention, diagnosis, and treatment of diseases. Despite continuous technological progress, drug development remains an extremely inefficient process. Statistical analyses indicate that the average time required to develop a new pharmaceutical compound ranges from 10 to 15 years, while the average cost exceeds 2.6 billion US dollarsper approved drug. Furthermore, clinical trial data show that only one out of ten drug candidates successfully reaches the market. These limitations demonstrate the urgent need for innovative approaches capable of improving efficiency and reducing failure rates.

Artificial intelligence represents one of the most significant technological advancements addressing these challenges. AI systems are capable of processing large-scale chemical, biological, and clinical datasets that exceed human analytical capacity. In medical chemistry, artificial intelligence is applied to identify molecular patterns, predict biological activity, estimate toxicity, and optimize chemical reactions. Unlike traditional computational methods, AI algorithms continuously improve their performance through learning from data, leading to progressively more accurate predictions. As a result, artificial intelligence has shifted medical chemistry from a trial-and-error approach toward data-driven decision-making.

MAIN BODY

Materials and Methods

In this study, artificial intelligence (AI) methods were analyzed for their application in medical chemistry, particularly in drug discovery and reaction prediction. Data were collected from peer-reviewed scientific articles focusing on machine learning models such as neural networks and deep learning algorithms used in chemical analysis. Molecular structures were represented using SMILES notation and molecular descriptors.

AI-based reaction prediction tools were evaluated for their ability to model biochemical and pharmaceutical reactions. As an example, ester hydrolysis reactions, commonly involved in drug metabolism, were analyzed:

$$R–COO–R' + H_2O \rightarrow R–COOH + R'–OH$$

Additionally, oxidation reactions catalyzed by cytochrome P450 enzymes were considered, as these reactions are crucial in medical chemistry for predicting drug biotransformation:

$$RH + O_2 + NADPH + H^+ \rightarrow ROH + H_2O + NADP^+$$

The performance of AI models was assessed by comparing predicted reaction outcomes with experimentally validated data reported in the literature.

ISSN 3030-3907

RESULTS AND DISCUSSION

The results demonstrated that artificial intelligence significantly improves the accuracy of predicting chemical reactions relevant to medical chemistry. AI models successfully identified reaction pathways and predicted major metabolites formed during drug metabolism. For example, AI-based systems accurately predicted ester hydrolysis as a primary metabolic reaction for prodrug molecules.

Furthermore, AI algorithms showed high reliability in predicting oxidation reactions mediated by cytochrome P450 enzymes, which are essential for assessing drug safety and efficacy. These findings confirm that AI reduces experimental time and cost by minimizing trial-and-error approaches in chemical synthesis and metabolic studies. The integration of artificial intelligence into medical chemistry enhances rational drug design and supports the development of safer and more effective pharmaceuticals.

The application of artificial intelligence in medical chemistry has transformed drug discovery by enabling rapid virtual screening of chemical libraries. Conventional high-throughput screening requires physical testing of thousands of compounds and often takes several months. In contrast, AI-based virtual screening systems can evaluate over one million chemical structures within a single day. Studies have demonstrated that machine learning models improve hit identification rates by 30–40 percent compared to classical quantitative structure–activity relationship methods. A clear example of this advancement is the AI-designed drug candidate DSP-1181, developed for the treatment of obsessive-compulsive disorder. The molecule was designed and optimized in less than twelve months, whereas traditional preclinical development typically requires four to five years. Artificial intelligence also plays a critical role in molecular design and binding affinity prediction. Advanced neural networks analyze molecular structures as graphs, allowing precise modeling of atomic interactions. These models predict binding free energy values, hydrogen bonding patterns, steric compatibility, and hydrophobic interactions between drug molecules and biological targets. Comparative studies have shown that AI-assisted docking increases binding affinity prediction accuracy by up to 25 percent compared to conventional docking software alone. This improvement directly reduces the synthesis of ineffective compounds and lowers laboratory costs.

Chemical synthesis planning represents another major application of artificial intelligence in medical chemistry. AI-powered retrosynthesis tools are trained on millions of published chemical reactions and are capable of predicting optimal synthetic pathways for complex pharmaceutical compounds. These systems accurately forecast reaction yields, identify suitable reagents, and

ISSN 3030-3907

recommend reaction conditions such as solvent type and temperature. Experimental evidence indicates that AI-assisted synthesis reduces the number of laboratory trial steps by 50–60 percent and achieves yield prediction accuracy levels of approximately 80–90 percent. Such optimization significantly accelerates pharmaceutical manufacturing and enhances laboratory safety.

Toxicity prediction remains one of the most critical challenges in drug development, as toxic effects are the leading cause of clinical trial failure. Artificial intelligence models trained on toxicological databases demonstrate high predictive accuracy for multiple toxicity endpoints. AI systems can predict hepatotoxicity with up to 90 percent accuracy, cardiotoxicity related to hERG channel inhibition with approximately 88 percent accuracy, and mutagenicity with sensitivity exceeding 90 percent. Early identification of toxic compounds prevents unsafe molecules from entering clinical trials, reduces animal testing, and improves patient safety. Furthermore, AI-based ADMET prediction shortens early-stage drug development by an estimated two to three years. In addition, artificial intelligence supports the advancement of personalized medicine by integrating chemical data with patient-specific genomic and metabolic information. In oncology, AI-guided drug selection based on molecular biomarkers has been shown to improve treatment response rates by 20–30 percent while reducing adverse drug reactions by up to 40 percent. Medical chemistry benefits from this approach by enabling the design of highly selective drugs that target specific molecular pathways, minimizing systemic toxicity and maximizing therapeutic efficacy.

Artificial intelligence has also demonstrated high effectiveness in the analysis of protein structure and function, which is a fundamental aspect of medical chemistry. The determination of protein–ligand interactions traditionally requires labor-intensive experimental techniques such as X-ray crystallography and nuclear magnetic resonance spectroscopy. These methods are accurate but expensive and time-consuming. AI-based structure prediction models significantly accelerate this process. A notable example is AlphaFold, which achieved protein structure prediction accuracy comparable to experimental methods. By 2022, AlphaFold had predicted the structures of more than 200 million proteins, covering almost the entire known protein universe. This achievement has provided medical chemists with direct access to structural data that are essential for rational drug design and enzyme inhibition studies.

In the field of enzyme kinetics, artificial intelligence models are used to predict inhibition constants (Ki) and half-maximal inhibitory concentrations (IC50) based on molecular structure. Studies show that machine learning models can

ISSN 3030-3907

predict IC50 values with correlation coefficients exceeding 0.85 when compared to experimental results. This level of accuracy allows chemists to prioritize the most promising compounds before synthesis. As a result, the number of synthesized molecules per project is reduced by approximately 40–50 percent, significantly lowering material and labor costs.

Artificial intelligence also plays an important role in the optimization of drug formulation and stability. In medical chemistry, the stability of active pharmaceutical ingredients is critical for maintaining therapeutic efficacy. AI algorithms analyze degradation pathways, temperature sensitivity, pH dependence, and excipient compatibility. Predictive models have demonstrated the ability to forecast degradation rates with an error margin of less than 10 percent. This enables the rational selection of stabilizing agents and packaging conditions, reducing product failure during storage and transportation.

Artificial intelligence (AI) has significantly accelerated drug discovery by enabling high-throughput virtual screening of chemical compounds. Machine learning algorithms analyze large molecular datasets to predict bioactivity and pharmacokinetic properties, reducing the need for extensive laboratory experiments. For example, deep learning models can forecast potential drug-target interactions with high accuracy, helping chemists prioritize compounds for synthesis and testing. Additionally, AI-assisted molecular modeling allows precise optimization of compound structures, improving efficacy while minimizing toxicity.

AI also enhances chemical synthesis planning through automated reaction prediction. By integrating symbolic AI and neural networks, researchers can identify feasible synthetic pathways for complex molecules, reducing time and cost in laboratory synthesis. Moreover, AI platforms analyze genomic, proteomic, and metabolomic data to support personalized medicine approaches, ensuring that new therapeutics are tailored to patient-specific molecular profiles. This integration of AI tools into medicinal chemistry is transforming traditional workflows, leading to more efficient and precise drug development.

Another important application of artificial intelligence is the identification of novel drug targets. AI systems analyze gene expression profiles, protein–protein interaction networks, and metabolic pathways to detect disease-associated molecular targets. In recent studies, AI-driven target discovery increased the identification of viable therapeutic targets by approximately 25 percent compared to conventional bioinformatics approaches. This is particularly significant in complex diseases such as Alzheimer’s disease, cancer, and autoimmune disorders, where multiple molecular pathways are involved.

ISSN 3030-3907

Artificial intelligence has further contributed to the development of antiviral and antimicrobial agents. During the COVID-19 pandemic, AI-based drug repurposing platforms analyzed existing pharmaceutical compounds and identified several candidates with potential antiviral activity within weeks. Traditional screening approaches would have required several months. In antimicrobial research, AI models predict bacterial resistance patterns and assist in the design of antibiotics that are less susceptible to enzymatic degradation. This application is especially important given the global increase in antimicrobial resistance, which is responsible for an estimated 1.27 million deaths annually worldwide.

In computational toxicology, artificial intelligence enables multi-endpoint risk assessment by integrating chemical structure data with biological response models. AI-based systems can simultaneously predict acute toxicity, chronic toxicity, genotoxicity, and endocrine-disrupting potential.

CONCLUSION

Artificial intelligence has introduced measurable and scientifically validated improvements in medical chemistry. Documented evidence confirms that AI-based approaches significantly reduce drug development time, increase prediction accuracy, and lower financial risk. Reductions of up to 60 percent in experimental workload, substantial cost savings, and improved patient safety outcomes clearly demonstrate the value of artificial intelligence in pharmaceutical research. Although experimental validation remains essential, artificial intelligence has become an indispensable analytical tool that enhances decision-making and accelerates innovation. In conclusion, artificial intelligence is no longer an auxiliary technology but a core scientific component shaping the future of medical chemistry.

REFERENCES

1. 1.Schneider, G. “Automating drug discovery.” Nature Reviews Drug Discovery.
2. Vamathevan, J. et al. “Applications of machine learning in drug discovery and development.” Nature Reviews Drug Discovery.
3. Zhavoronkov, A. “Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry.” Molecular Pharmaceutics.
4. Segler, M.H.S., Preuss, M., Waller, M.P. “Planning chemical syntheses with deep neural networks and symbolic AI.” Nature, 2018.
5. Chen, H. et al. “The rise of deep learning in drug discovery.” Drug Discovery Today, 2018.
6. Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery.

ISSN 3030-3907

7. Yang, X., Zhang, J., Yoshizoe, K., Terayama, K., & Tsuda, K. (2017). ChemTS: An efficient Python library for de novo molecular generation. Science and Technology of Advanced Materials.

ISSN 3030-3907